Chapter 1. Research Background
1.1. Research Objectives
1.2. Market Definition
1.3. Research Scope
1.3.1. Market Segmentation by Route of Administration
1.3.2. Market Segmentation by Application
1.3.3. Market Segmentation by Marketing Type
1.3.4. Market Segmentation by Geography
1.3.5. Analysis Period
1.3.6. Market Data Reporting Unit
1.4. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By region
2.2.1.2. By industry participants
2.2.1.3. By company type
2.3. Market Size Estimation
2.4. Market Breakdown and Data Triangulation
2.5. Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1. Market Segmentation
4.1.1. Overview by Route of Administration
4.1.1.1. Oral Route
4.1.1.2. Parenteral route
4.1.2. Overview by Application
4.1.2.1. Cancer
4.1.2.2. Central nervous system
4.1.2.3. Respiratory disorders
4.1.2.4. Metabolic disorders
4.1.2.5. Cardiovascular
4.1.2.6. Infection
4.1.2.7. Hematological disorders
4.1.2.8. Gastrointestinal disorders
4.1.2.9. Acromegaly
4.1.2.10. Others
4.1.3. Overview by Marketing Type
4.1.3.1. Branded peptide therapeutics
4.1.3.2. Generic peptide therapeutics
4.2. Market Dynamics
4.2.1. Trends
4.2.2. Drivers
4.2.2.1. Impact analysis of drivers on market forecast
4.2.3. Restraints
4.2.3.1. Impact analysis of restraints on market forecast
4.2.4. Opportunities
4.3. Porter’s Five Forces Analysis
Chapter 5. Market Size and Forecast by Route of Administration
5.1. Oral Route
5.2. Parenteral Route
Chapter 6. Market Size and Forecast by Application
6.1. Cancer
6.2. Central Nervous System
6.3. Respiratory Disorders
6.4. Metabolic Disorders
6.5. Cardiovascular
6.6. Infection
6.7. Hematological Disorders
6.8. Gastrointestinal Disorders
6.9. Acromegaly
6.10. Others
Chapter 7. Market Size and Forecast by Marketing Type
7.1. Branded Peptide Therapeutics
7.2. Generic Peptide Therapeutics
Chapter 8. Market Size and Forecast by Geography
8.1. North America Peptide Therapeutics Market
8.1.1. By Route of Administration
8.1.2. By Application
8.1.3. By Marketing Type
8.1.4. By Country – The U.S and Canada
8.2. Europe Peptide Therapeutics Market
8.2.1. By Route of Administration
8.2.2. By Application
8.2.3. By Marketing Type
8.2.4. By Country –Germany, France, The U.K and rest of Europe
8.3. Asia-Pacific Peptide Therapeutics Market
8.3.1. By Route of Administration
8.3.2. By Application
8.3.3. By Marketing Type
8.3.4. By Country -China, Japan, India and Rest of Asia-Pacific
8.4. Latin America Peptide Therapeutics Market
8.4.1. By Route of Administration
8.4.2. By Application
8.4.3. By Marketing Type
8.4.4. By Country – Brazil, Mexico and Rest of Latin America
8.5. Middle East & Africa Peptide Therapeutics Market
8.5.1. By Route of Administration
8.5.2. By Application
8.5.3. By Marketing Type
Chapter 9. Competitive Landscape
9.1. Competitive Analysis of Key Players
9.2. Global Strategic Developments
Chapter 10. Company Profiles
10.1. Bachem Holding AG
10.1.1. Business Overview
10.1.2. Product and Service Offerings
10.1.3. Key Financial Summary
10.1.4. Strategic Growth Plan
10.2. Amgen, Inc.
10.2.1. Business Overview
10.2.2. Product and Service Offerings
10.2.3. Key Financial Summary
10.2.4. Strategic Growth Plan
10.3. AstraZeneca plc
10.3.1. Business Overview
10.3.2. Product and Service Offerings
10.3.3. Key Financial Summary
10.3.4. Strategic Growth Plan
10.4. Merck & Co. Inc.
10.4.1. Business Overview
10.4.2. Product and Service Offerings
10.4.3. Key Financial Summary
10.4.4. Strategic Growth Plan
10.5. Eli Lily and Company
10.5.1. Business Overview
10.5.2. Product and Service Offerings
10.5.3. Key Financial Summary
10.5.4. Strategic Growth Plan
10.6. CordenPharma International GmbH
10.6.1. Business Overview
10.6.2. Product and Service Offerings
10.6.3. Key Financial Summary
10.6.4. Strategic Growth Plan
10.7. Ipsen S.A.
10.7.1. Business Overview
10.7.2. Product and Service Offerings
10.7.3. Key Financial Summary
10.7.4. Strategic Growth Plan
10.8. Novartis AG
10.8.1. Business Overview
10.8.2. Product and Service Offerings
10.8.3. Key Financial Summary
10.8.4. Strategic Growth Plan
10.9. PolyPeptide Group
10.9.1. Business Overview
10.9.2. Product and Service Offerings
10.9.3. Key Financial Summary
10.9.4. Strategic Growth Plan
10.10. F. Hoffmann-La Roche AG
10.10.1. Business Overview
10.10.2. Product and Service Offerings
10.10.3. Key Financial Summary
10.10.4. Strategic Growth Plan
10.11. Novo Nordisk A/S
10.11.1. Business Overview
10.11.2. Product and Service Offerings
10.11.3. Key Financial Summary
10.11.4. Strategic Growth Plan
10.12. Sanofi
10.12.1. Business Overview
10.12.2. Product and Service Offerings
10.12.3. Key Financial Summary
10.12.4. Strategic Growth Plan
10.13. Teva Pharmaceutical Industries Ltd.
10.13.1. Business Overview
10.13.2. Product and Service Offerings
10.13.3. Key Financial Summary
10.13.4. Strategic Growth Plan
*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.
Chapter 11. Appendix
11.1. Abbreviations
